|
|
||||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada
Division of Clinical Pharmacology and Pharmacy and Glaxo Wellcome-Sunnybrook Drug Safety Clinic, Toronto, Ontario, Canada
Department of Medicine, Division of Clinical Pharmacology and Pharmacy, Toronto, Ontario, Canada; Sunnybrook Health Science Centre, University of Toronto, and the Kunin-Lunenfeld Clinical Research Unit, Baycrest Centre for Geriatric Care, Toronto, Ontario, Canada
Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada; Division of Clinical Pharmacology and Pharmacy and Glaxo Wellcome-Sunnybrook Drug Safety Clinic, Toronto, Ontario, Canada; Department of Medicine, Division of Clinical Pharmacology and Pharmacy, Toronto, Ontario, Canada
The objective of this study is to identify gender-related differences in the types of symptoms and drugs reported to cause an adverse drug reaction. Patient data from the Sunnybrook Health Science Centre ADR Clinic for the period from April 1986 to May 1996 were reviewed. Of the 2,367 patients assessed, 74.1% were female. The mean age of the patients was 43 ± 17 years. Drug classes most frequently reported to elicit an adverse event were general antiinfectives (60.4%), nervous system agents (21.5%), and musculoskeletal agents (3.7%). Skin-related reactions accounted for 49.0% of all reported adverse drug realtions. More than one agent was reported to be responsible for the adverse drug reaction(s) in 50% of the female patients, versus 33.1% of all male patients. Of the female patients, 47.6% were referred for skin or oral challenge testing, versus 41.6% of the male patients. Of the female patients, 6.2% tested positive to the agent compared with 6.1% of all male patients. These results support previous findings that female gender is a risk factor for the development of adverse drug reactions. Further work is required to elucidate the mechanisms explaining the differences observed between male and female patients.
This article has been cited by other articles:
![]() |
V. Essebag, M. R. Reynolds, T. Hadjis, R. Lemery, B. Olshansky, A. E. Buxton, M. E. Josephson, and P. Zimetbaum Sex Differences in the Relationship Between Amiodarone Use and the Need for Permanent Pacing in Patients With Atrial Fibrillation Arch Intern Med, August 13, 2007; 167(15): 1648 - 1653. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. K Al-Tajir and W. N Kelly Epidemiology, Comparative Methods of Detection, and Preventability of Adverse Drug Events Ann. Pharmacother., July 1, 2005; 39(7): 1169 - 1174. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Corsonello, C. Pedone, F. Corica, C. Mussi, P. Carbonin, R. Antonelli Incalzi, and for the Gruppo Italiano di Farmacovigilanza nell'A Concealed Renal Insufficiency and Adverse Drug Reactions in Elderly Hospitalized Patients Arch Intern Med, April 11, 2005; 165(7): 790 - 795. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Torpet, C. Kragelund, J. Reibel, and B. Nauntofte ORAL ADVERSE DRUG REACTIONS TO CARDIOVASCULAR DRUGS Crit. Rev. Oral. Biol. Med., January 1, 2004; 15(1): 28 - 46. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Onder, M. Cesari, and R. Bernabei Depression and Adverse Drug Reactions Arch Intern Med, October 27, 2003; 163(19): 2395 - 2395. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |